SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers Health is currently generating intense debate among retail traders, fueled by significant short interest and speculation regarding potential partnerships and the reclassification of peptides. While the community is divided between those bracing for a violent short squeeze driven by upcoming earnings and regulatory catalysts, others remain deeply skeptical due to recent insider selling and inconsistent price action relative to broader market momentum.

Rumble, Inc. engages in operating an online neutral video platform. It operates through the following geographical segments: United States, Canada, and Other. The company was founded in October 2013 by Chris Pavlovski and is headquartered in Longboat Key, FL.

Rumble Inc - Ordinary Shares - Class A

Rumble Inc

Rumble is experiencing significant investor interest driven by its pending acquisition of Northern Data and strategic investment commitments from Tether, which have sparked intense discussion regarding a potential short squeeze. With record-high short interest and a limited tradable float, the community is closely tracking the progress of the acquisition and speculating on how these institutional catalysts could force shorts to cover their positions.

XRP is a decentralized digital asset and the native token of the XRP Ledger, a Layer 1 blockchain designed for high-performance global payments. Its primary value proposition is offering a fast, cost-effective alternative to traditional banking systems by enabling near-instant cross-border settlements that finalize in three to five seconds. By serving as a neutral bridge asset between different fiat currencies, it helps financial institutions lower liquidity costs and eliminates the need for pre-funded accounts.  The network is unique because it utilizes a federated consensus protocol instead of energy-intensive mining or staking. This system achieves deterministic finality through a Unique Node List of trusted validators who must reach an eighty percent agreement threshold to permanently record transactions. This infrastructure supports a sustained throughput of 1,500 transactions per second and includes a built-in decentralized exchange that allows for the automated trading of any tokenized asset without intermediaries.  The project traces its origins back to 2004 with Ryan Fugger before being co-founded in its modern form by Jed McCaleb and Chris Larsen. The company, now known as Ripple, works with major financial institutions as partners and investors to build global payment solutions. To protect the network from spam, a small amount of XRP is burned during every transaction, and the token is further utilized by institutions as collateral to access traditional markets and manage digital asset infrastructure.  Institutional adoption of the asset reached a major milestone in November 2025 when the SEC approved the first wave of spot XRP ETFs. These products, offered by major issuers including Bitwise, Grayscale, 21Shares, Canary Capital, and Franklin Templeton, are now listed on prominent exchanges like the NYSE Arca, Nasdaq, and Cboe BZX. While Ripple remains a key contributor to the ecosystem, the underlying XRP Ledger continues to operate as an open-source and decentralized network.

Ripple

Ripple's XRP remains a major point of contention among traders, as ongoing debates regarding the Clarity Act, potential institutional adoption, and recent developments in Japanese markets fuel speculative volatility. While some participants are actively accumulating due to long-term utility narratives and liquidity expectations, others remain frustrated by the asset's persistent decoupling from broader market rallies and its history of price stagnation.

Berkshire Hathaway, Inc. is a holding company, which engages in the provision of property and casualty insurance and reinsurance, utilities and energy, freight rail transportation, finance, manufacturing, and retailing services. It operates through the following segments: Insurance, Burlington Northern Santa Fe, LLC (BNSF), Berkshire Hathaway Energy (BHE), Pilot Travel Centers (PTC), Manufacturing, McLane, and Service and Retailing. The Insurance segment includes the underwriting of GEICO, Berkshire Hathaway Primary Group, and Berkshire Hathaway Reinsurance Group. The BNSF segment involves the operation of railroad systems. The BHE segment focuses on regulated electric and gas utility, power generation and distribution, and real estate brokerage activities. The PTC segment consists of managing travel centers and marketing of wholesale fuel. The Manufacturing segment refers to industrial, consumer and building products, home building, and related financial services. The McLane segment covers the wholesale distribution of groceries and non-food items. The Service and Retailing segment relates to the provision of shared aircraft ownership programs, aviation pilot training, electronic components distribution, retailing businesses, automobile dealerships and trailer, and furniture leasing services. The company was founded by Oliver Chace in 1839 and is headquartered in Omaha, NE.

Berkshire Hathaway Inc. - Ordinary Shares - Class B

Berkshire Hathaway is seeing intense investor debate as the stock faces continued underperformance relative to major indices, leading to friction between shareholders expecting growth and those advocating for capital preservation. The conversation is dominated by frustration over the company's massive cash pile, skepticism regarding the leadership transition to Greg Abel, and mixed reactions to the resumption of share buybacks.

Xanadu Quantum Technologies Ltd. engages in the provision of quantum computing solutions for enterprise and government customers. The company was founded by Christian Weedbrook on October 2, 2025 and is headquartered in Toronto, Canada.

Xanadu Quantum Technologies Ltd. - Ordinary Shares - Class B (Sub Voting)

Xanadu Quantum Technologies is attracting significant investor attention as a pure-play photonic quantum computing company following its recent public debut. The community is actively debating the potential for a short squeeze driven by a low float and high borrow rates, while others focus on its strategic partnerships with major industry leaders.

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. It provides customers with access to the company’s quantum computing systems via the cloud in the form of quantum computing as a service. It offers professional services such as customer assistance in identifying and implementing quantum-computing applications. The company was founded on January 25, 2022 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

D-Wave Quantum is trending as investors weigh aggressive short-term call buying against concerns over competition from IBM's recent quantum computing advancements. While some traders are attempting to bottom-fish the pullback, others remain cautious due to the company's valuation and the ongoing volatility across the broader quantum sector.

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is currently experiencing heightened volatility following news of Amazons acquisition of Globalstar, which market participants are misinterpreting as a direct competitive threat to ASTS's proprietary broadband technology. While the community is actively debating the impact of the deal, long-term investors are viewing the dip as an accumulation opportunity, emphasizing that ASTS's unique direct-to-device broadband capabilities remain distinct from the limited narrowband services offered by competitors.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is trending following the official launch of Power Packs, a digital trading card platform that allows collectors to buy and trade PSA-graded assets. While some in the community remain skeptical of the stock's sluggish price movement, others are closely watching for signs of a potential short squeeze as they analyze long-term acquisition strategies and revenue growth opportunities.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

SPY has surged to a historic milestone, with the market brushing off macro concerns and war-related uncertainty to achieve new all-time highs. The community is sharply divided, with bulls celebrating the aggressive upward momentum and gamma-driven squeeze, while skeptics warn of a potential bull trap fueled by algorithmic trading and disconnects from traditional economic fundamentals.

Taiwan Semiconductor Manufacturing Co., Ltd. engages in the manufacture and sale of integrated circuits and wafer semiconductor devices. Its chips are used in personal computers and peripheral products, information applications, wired and wireless communications systems products, and automotive and industrial equipment including consumer electronics such as smartphones, digital television, game consoles, and digital cameras. The company was founded by Chung Mou Chang on February 21, 1987 and is headquartered in Hsinchu, Taiwan.

Taiwan Semiconductor Manufacturing - ADR

TSM is trending as investors aggressively position themselves ahead of the upcoming earnings report, with significant call flow activity suggesting strong bullish sentiment despite ongoing geopolitical concerns regarding chip production and energy supply. The community is actively debating the company's long-term manufacturing moat against competitors and monitoring potential supply chain bottlenecks in AI-critical materials.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Ligand Pharmaceuticals (NASDAQ:LGND) Sets New 12-Month High Following Analyst Upgrade

Ligand Pharmaceuticals (NASDAQ:LGND) Reaches New 52-Week High Following Analyst Upgrade...

Ligand Pharmaceuticals (NASDAQ:LGND) Given New $243.00 Price Target at HC Wainwright

HC Wainwright upped their price objective on Ligand Pharmaceuticals from $239.00 to $243.00 and gave the company a "buy" rating in a research report on Tuesday...

<ul class="summary-bullets"><li>On Monday, the U.S. FDA approved Filspari to reduce proteinuria in patients with focal segmental glomerulosclerosis, a rare kidney disorder.</li><li>The company estimates that over 30,000 people in the U.S. with FSGS without nephrotic syndrome could be eligible for the treatment.</li><li>Citi does not see a commercial setback despite a narrower label, according to The Fly.</li></ul>Shares of Travere Therapeutics (TVTX) surged more than 40% in pre-market trading on Tuesday as bullish analyst reactions followed the U.S. Food and Drug Administration (FDA) approval of the company’s Filspari for a rare kidney disorder, making it the first approved treatment for the condition.If the premarket levels hold after the opening bell, <a href="https://stocktwits.com/symbol/TVTX">TVTX shares</a> would surge to their highest since May 2005.<h2 class="st-heading-2">Filspari Becomes The Only Approved FSGS Treatment</h2>On Monday, the U.S. FDA approved Filspari to reduce proteinuria in patients with focal segmental glomerulosclerosis (FSGS). FSGS is a serious condition that causes protein leakage in urine, leading to progressive kidney damage and potential failure. The company estimates that over 30,000 people in the U.S. with FSGS without nephrotic syndrome could be eligible for the treatment.The decision follows a delayed review prompted by the FDA's request for additional data. Approval was supported by late-stage trial results showing Filspari reduced proteinuria by 48% over 108 weeks.Brokerages turned bullish on Travere Therapeutics following the FDA approval. Canaccord raised its price target to $56 from $47 and maintained a ‘Buy’ rating, according to The Fly, projecting peak sales of $547 million for the drug by 2032.Citi analyst Yigal Nochomovitz increased the firm’s price target to $53 from $48, keeping a ‘Buy’ rating. Citi said the approval in FSGS supports the increased target, adding that the narrower label is not seen as a commercial setback. Bank of America also lifted its target to $49 from $44 and reiterated a ‘Buy’ rating on the stock.<h2 class="st-heading-2">How Did Retail Traders React?</h2>Retail sentiment on Stocktwits remained in the ‘extremely bullish’ zone over the past 24 hours. Messages on the platform increased a whopping 3,200% during the same period, according to Stocktwits data.&nbsp;&nbsp;One user expects “swift uptake for this medicine.”<stembedurl>https://stocktwits.com/pblegend66/message/650201899</stembedurl>Year-to-date, the stock has slid around 21%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Travere Therapeutics logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

TVTX Stock On Track To Hit Near 20-Year Highs After Filspari Becomes The Only Approved FSGS Treatment

Canaccord projected peak sales of $547 million for the drug by 2032, according to The Fly.

Equity

<ul><li>The agency approved the drug in adult and pediatric patients aged 8 years and older.</li><li>Travere expects that there are at least 30,000 people in the U.S. with focal segmental glomerulosclerosis but without nephrotic syndrome. &nbsp;</li><li>Filspari was previously greenlit by the FDA for the treatment of IgA nephropathy.</li></ul>Travere Therapeutics, Inc. (TVTX) said on Monday that the U.S. Food and Drug Administration has approved its Filspari to reduce proteinuria in some patients with focal segmental glomerulosclerosis (FSGS), making it the first FDA-approved drug for the indication.The agency approved the drug in adult and pediatric patients aged 8 years and older. Travere expects that there are at least 30,000 people in the U.S. with focal segmental glomerulosclerosis but without nephrotic syndrome.Filspari was previously greenlit by the FDA for the treatment of IgA nephropathy, a chronic autoimmune kidney disease characterized by the abnormal accumulation of immunoglobulin A (IgA) antibodies in the kidneys' filtering units.<h2 class="st-heading-2">Fresh Approval</h2>While the FDA was previously expected to decide on Travere’s application by January, it pushed it to April after requesting additional information to assess Filspari’s clinical benefit. The company submitted responses, and the agency determined that the responses constitute a major amendment to the application, and extended the review timeline.Filspari was approved in the new indication based on data from a late stage trial where FSGS patients without nephrotic syndrome who were treated with Filspari experienced a 48% reduction in proteinuria from baseline to week 108 compared to 27% for those treated with irbesartan.FSGS is a rare and serious kidney disorder driven by proteinuria or protein leaks into the urine due to a breakdown of the normal filtration mechanism in the kidney. The disease leads to progressive kidney function loss and kidney failure.While TVTX edged 0.2% lower after hours, shares of Ligand Pharmaceuticals (LGND), with which Travere has a licensing agreement for Sparsentan, sold under the Filspari brand, rose 3% at the time of writing.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around TVTX stock stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘extremely high’ levels.<a href="https://stocktwits.com/symbol/TVTX">TVTX</a> has gained 107% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/aal-stock-advances-after-hours-following-report-of-ual-ceo-combining-his-past-and-present-companies/cZJ8WmWRIuC">AAL Stock Advances After-Hours Following Report Of UAL CEO Combining His Past And Present Companies</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Travere Therapeutics Wins Much-Awaited Approval For Drug In Rare Kidney Disease

The FDA approved Filspari to reduce proteinuria in some patients with focal segmental glomerulosclerosis.

<ul class="summary-bullets"><li>The FDA had extended the review of its supplemental New Drug Application for Filspari in January 2026.</li><li>Citi kept a $48 price target for Travere, adding that it expects the FDA to approve the drug.</li><li>If approved, Filspari would become the first treatment specifically indicated for FSGS, a rare kidney disorder.</li></ul>Shares of Travere Therapeutics (TVTX) and Ligand Pharmaceuticals (LGND) are drawing increased investor attention ahead of a key U.S. Food and Drug Administration decision on Filspari, a treatment for a rare kidney disease, expected on April 13.Ligand has a licensing agreement with Travere for Sparsentan, sold under the Filspari brand, under which Ligand will receive milestone payments and a 9% royalty on future global net sales of the drug.At the time of writing, <a href="https://stocktwits.com/symbol/TVTX">TVTX</a> and <a href="https://stocktwits.com/symbol/LGND">LGND</a> shares were little changed in pre-market trading on Friday.<h2 class="st-heading-2">FDA Did Not Seek Additional Information On Safety And Manufacturing</h2>In January, Travere Therapeutics announced that the FDA extended the review of its supplemental New Drug Application (sNDA) for Filspari in focal segmental glomerulosclerosis (FSGS), setting a Prescription Drug User Fee Act (PDUFA) target action date of April 13, 2026. The FDA did not request any additional information related to the drug’s safety or manufacturing.A PDUFA date is the FDA’s target date for making a decision on a drug application, which allows the drug to be marketed in the U.S.If approved, Filspari would become the first treatment specifically indicated for FSGS, a rare kidney disorder that can lead to progressive loss of kidney function and eventual kidney failure. Filspari is an oral, non-immunosuppressive therapy.<h2 class="st-heading-2">Citi Expects FDA Approval</h2>Last month, Citi maintained Travere Therapeutics’ ‘Buy’ rating and $48 price target. The firm expects the FDA to approve Filspari and added that the current share price does not fully reflect the company’s opportunity in FSGS.Travere’s Phase 3 study met its interim goal for proteinuria reduction but did not meet the primary kidney function endpoint. However, longer-term results showed the drug improved proteinuria, remission rates, and reduced progression to kidney failure, while remaining well-tolerated. Proteinuria is the high concentration of protein, usually albumin, in urine.<h2 class="st-heading-2">How Did Retail Traders React?</h2>Retail sentiment on Stocktwits was ‘bullish’ for TVTX and ‘neutral’ for LGND.One user expects TVTX stock to decline if there is no update before Friday’s close.<stembedurl>https://stocktwits.com/Smellmahass/message/649764886</stembedurl>However, another user expected a pre-FDA run-up to $32 - $35.<stembedurl>https://stocktwits.com/Buckeyeboy722/message/649091978</stembedurl>Year-to-date, TVTX shares have declined 20% while LGND stock has gained around 5%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Travere Therapeutics, Ligand In Focus As FDA Set To Rule On Filspari Next Week – First FSGS Drug At Stake 

The FDA is expected to announce its decision on Filspari, a drug to treat focal segmental glomerulosclerosis, a type of kidney ailment.

TVTX, LGND Stocks In Spotlight Ahead Of Monday’s FDA Call On Kidney Drug Filspari

Ligand Pharmaceuticals (NASDAQ:LGND) Stock Acquired Rep. Gilbert Ray Cisneros, Jr.

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND). In a filing disclosed on April 07th, the Representative disclosed that they had bought between $1,001 and $15,000 in Ligand Pharmaceuticals stock on March 3rd...

Aberdeen Group plc Lowers Stock Position in Ligand Pharmaceuticals Incorporated $LGND

Aberdeen Group plc cut its holdings in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) by 37.1% during the fourth quarter, according to the company in its most recent...

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Get Free Report) has received a consensus rating of "Moderate Buy" from the eight analysts that are covering the firm, Marketbeat.com reports. One...

Allspring Global Investments Holdings LLC Has $13.65 Million Position in Ligand Pharmaceuticals Incorporated $LGND

Allspring Global Investments Holdings LLC lessened its holdings in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) by 33.8% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 71,818...

Insider Selling: Ligand Pharmaceuticals (NASDAQ:LGND) Insider Sells 5,000 Shares of Stock

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Get Free Report) insider Andrew Reardon sold 5,000 shares of the stock in a transaction on Wednesday, April 1st. The stock was sold at an average...

Ligand Pharmaceuticals, Inc. is a biopharmaceutical company that involves clinical development and commercialization of high-value medicines. Its platforms, Captisol and NITRICI, offer technology with broad applicability in drug development to a large network of biopharmaceutical partners, including the largest pharmaceutical manufacturers in the world. The company was founded by Ronald M. Evans in 1987 and is headquartered in Jupiter, FL.

LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares - Class B

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest LGND News

LGNDLigand Pharmaceuticals, Inc. - Ordinary Shares - Class B